STOCKHOLM, SWEDEN/ACCESSWIRE/March 22, 2022/ AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in Alzheimer’s disease and pain, has today announced that two abstracts on its NeuroRestore research platform have been accepted for poster presentation at the 2nd Swedish Meeting for Alzheimer’s Research, to be held this year in Stockholm on April 21.
The summaries, titled Results of a Single-Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Trk Neurotrophin Receptor Modulator, and A positive modulator of neurotrophin receptors improves cognition and mitochondrial function, will be presented at the 2nd Swedish Meeting for Alzheimer’s Research by lead authors Kristin Önnestam and Dr. Cristina Parrado-Fernández. Other authors include Dr. Johan Sandin, CSO, Dr. Pontus Forsell, Chief Discovery Officer, and Dr. Märta Segerdahl, CMO at AlzeCure.
The results include data from the Phase I SAD clinical study with ACD856, where the drug candidate was administered orally to healthy individuals at incremental doses. The substance exhibited very good pharmacokinetic properties and had a good safety and tolerability profile in humans. ACD856, which is a positive modulator of NGF/TrkA and BDNF/TrkB-mediated signaling, has been shown in previous preclinical studies to improve cognition and memory and is being developed primarily for the treatment of Alzheimer’s disease .
Additionally, important new preclinical data are presented that show a dose-dependent positive effect of neurotrophins and the substance NeuroRestore AC-0027136 on mitochondrial function, which may be of key importance in neurodegenerative diseases, characterized by impaired of mitochondrial function. AC-0027136 was also able to significantly improve learning and long-term memory in aged animals.
“These results further strengthen our confidence in the target mechanism and demonstrate the magnitude of effects within the NeuroRestore platform. We look forward to the continued clinical development of ACD856 as a new treatment for Alzheimer’s disease, an indication with high medical need and we will also continue to explore other opportunities,” said Martin Jönsson, CEO of AlzeCure Pharma AB.
The abstract and the poster will be available on the AlzeCure website after the presentation (https://www.alzecurepharma.se/en/publications).
For more information please contact
Martin Jonsson, CEO
Tel: +46 707 86 94 43
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops innovative new drug therapies for the treatment of serious diseases and conditions affecting the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatments are very limited. The company is listed on the Nasdaq First North Premier Growth Market and is developing multiple parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates whose unique mechanism of action enables multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinsons. The Alzstatin platform focuses on the development of disease-modifying and preventive drug candidates for the early treatment of Alzheimer’s disease and includes two drug candidates. Painless is the company’s pain research platform and contains two projects: ACD440, which is a drug candidate in clinical development for the treatment of neuropathic pain, and TrkA-NAM, which targets pain intense in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through pre-clinical research and development to an early clinical phase, and continuously works on commercial development to find suitable licensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 [email protected], is the company’s certified advisor. For more information visit www.alzecurepharma.se
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive abilities are impaired, eg Alzheimer’s disease, sleep apnea, traumatic brain injury and Parkinson’s disease. NeuroRestore stimulates several important signaling pathways in the brain, which, among other things, leads to improved cognition. In preclinical studies with NeuroRestore, we were able to show that our drug candidates improve communication between nerve cells and improve cognitive abilities. NeuroRestore stimulates specific central nervous system signaling pathways called neurotrophins, the best known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). NGF and BDNF levels are disrupted in several disease states and signaling is reduced. The impaired function impairs communication between synapses, ie the contact surfaces of nerve endings, as well as the reduction of the possibility of survival of nerve cells, which leads to cognitive disorders. Neurotrophins play a crucial role for nerve cell function, and impaired BDNF function has a strong genetic link with impaired cognitive ability in several different diseases, such as Alzheimer’s disease, Parkinson’s disease, brain injury trauma and sleep disorders. There is also a link between BDNF signaling and depression, which has grown even stronger in recent years.
Martin Jönsson CEO of AlzeCure Pharma
AlzeCure Obtains Two NeuroRestore Abstracts Accepted at Alzheimer’s Conference
THE SOURCE: AlzéCure Pharma
See the source version on accesswire.com: